LY4302814
DrugAdministered SC
NCT Number: NCT07566338
The main purpose of this study is to assess how well LY4302814 is tolerated and what side effects may occur in healthy participants. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. For each participant, the study will last about 6 months and will include at least one overnight stay in the clinical research unit (CRU) lasting up to approximately 9 days.
Interested in participating?
Request Info18 year–65 year
All sexes
Interventional
Phase 1
Lilly Centre for Clinical Pharmacology, Singapore
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Administered SC
Administered SC
Time frame: Day 1 through Day 197
Time frame: Day 1 through Day 197
Time frame: Day 1 through Day 197
Contact information is provided by the study sponsor or research team.
Physicians interested in becoming principal investigators please contact
CONTACT
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
CONTACT
Eli Lilly and Company
Industry
A Phase 1, Randomized, Placebo-Controlled, Investigator and Participant Blinded, Single Ascending Dose and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4302814 in Healthy Participants
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07686393
Healthy
Bethesda, Maryland, United States
View Trial DetailsNCT07407348
Body Weight, Healthy
Nottingham, United Kingdom
View Trial DetailsNCT07169630
Alzheimer s Disease, Cognition Disorders
Bethesda, Maryland, United States
View Trial DetailsNCT01399385
Arterial Occlusive Diseases, Arteriosclerosis
Bethesda, Maryland, United States
View Trial Details